NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Beijing Anlong Biopharmaceutical Co., Ltd.

Beijing Anlong Biopharmaceutical Co., Ltd.

Private
BeijingHealthcare & Life Scienceshttp://www.anlongbio.com/

Last Round

Series B

Extension

Jan 7, 2026

Total Funding Raised

$58.2M

Company Overview

Beijing Anlong Biopharmaceutical Co., Ltd. is a biotechnology company that develops gene therapy products for the treatment of ophthalmological, neurological, and cardiovascular diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

gene therapyadeno-associated virusAAVwet age-related macular degenerationwAMDoligonucleotide therapeuticssiRNAbiotech drug discoveryvector engineeringclinical-stage biotechgenetic medicinedrug licensingophthalmology therapeuticsgene deliverybiopharma R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Beijing Anlong Biopharmaceutical Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Beijing Anlong Biopharmaceutical Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Beijing Anlong Biopharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 7, 2026
Series A ExtensionJan 23, 2024
Series AJun 9, 2021
VC RoundJan 8, 2021
Early FundingJul 8, 2020
Angel
Aug 9, 2019

Beijing Anlong Biopharmaceutical Co., Ltd. Investors

Notable investors and investment history

Beijing Anlong Biopharmaceutical Co., Ltd. investors
InvestorRounds
Tigeryeah CapitalSeries A
Oceanpine CapitalSeries A, VC Round
Anlong FundVC Round
Shanghai Honghui Asset ManagementSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 9, 2019

    $9M round led by Hangzhou Tigermed Consulting

Beijing Anlong Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Beijing Anlong Biopharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Beijing Anlong Biopharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBeijing
Employee Range43
Year Founded2019
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.